Category REGULATORY

FDA Approves Guardant360 CDx as Companion Diagnostic for AstraZeneca’s Camizestrant in Advanced Breast Cancer

Guardant Health’s Guardant360 CDx Receives FDA Approval for Camizestrant Companion Diagnostic in Advanced Breast Cancer Guardant Health, a precision oncology company focused on advancing cancer detection and treatment through genomic…

Read MoreFDA Approves Guardant360 CDx as Companion Diagnostic for AstraZeneca’s Camizestrant in Advanced Breast Cancer